Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Lone Star Fund and Stark Group in connection with the sale of the Stark Group to CVC Capital Partners.
Mandate

Vinge has advised Lone Star Fund and Stark Group in connection with the sale of the Stark Group to CVC Capital Partners.

January 08, 2021 Employment and Benefits M&A IT, Telecommunications and Outsourcing Corporate Crime & Compliance General Corporate Intellectual Property Real Estate and Construction

Headquartered in Denmark, STARK Group is a leading B2B distributor of heavy building materials for the construction industry in the Nordics and Germany, with a focus on serving professional craftsmen. The business partners with 10,000 suppliers to serve c. 235,000 customers from more than 400 locations in Denmark (incl. Greenland), Sweden, Norway, Finland, and Germany. The transaction is subject to customary conditions and approvals and is expected to close in Q2 2021.

Vinge’s team consisted of, among others, Jonas Bergström, Desirée Sjöblom, Vilhelm Rondahl and Amanda Steen (M&A), Michaela Cronemyr and Isabell Nielsen (Agreements), Frida Ställborn and Kristoffer Larson (Real Estate), Sara Strandberg and Caroline Edwall (Employment), Sofia Bergenstråhle (IP), Ludvig Wettergren and Jolinn Uhlin (Financial Arrangements), Fredrika Hjelmberg (IT), Nicklas Thorgerzon (GDPR), Lina Österberg (Permits), Tove Lövgren Frisk (Compliance) and the VDR assistant Carl Bruneheim.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026